



# WITHDRAWN: Efficacy and Side Effects of Sofosbuvir and Daclatasvir for Treatment of Hepatitis C in Thalassemia Major Patients with Treatment Experience of Interferon-Based Regimens

Jamshid Vafeimanesh  <sup>1,2</sup>, Fahimeh Safarnezhad Tameshkel  <sup>1</sup>, Hossein Ajdarkosh <sup>1</sup>, Azita Azarkeyvani <sup>3</sup>, Mahmoodreza Khoonsari <sup>1</sup>, Amirhossein Faraji <sup>1</sup>, Masoudreza Sohrabi <sup>1</sup>, Sima Aten <sup>1</sup>, Hossein Keyvani  <sup>1</sup>, Farhad Zamani <sup>1,\*</sup>

<sup>1</sup> Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, IR Iran

<sup>2</sup> Gastroenterology and Hepatology Disease Research Center, Qom University of Medical Sciences, Qom, IR Iran

<sup>3</sup> Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Department of Thalassemia Clinic, Tehran, IR Iran

\* Corresponding author: Farhad Zamani, Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, IR Iran. E-mail: zamani.farhad@gmail.com

Received: 17 January, 2018; Revised: 5 June, 2018; Accepted: 9 June, 2018

## Withdrawal Note

This article is withdrawn by EIC - on behalf of the editorial board- because of the case that it was published simultaneously in another journal (<https://www.ncbi.nlm.nih.gov/pubmed/30084415>). After

the investigation raised by EIC, authors confessed to their mistake in double submission (#346818) and due to the status of the article (In Press) and journal policy about withdrawal regulations (<http://hepatmon.com/en/knowledgebase/category/tree.html#withdrawal>) we decided to withdraw it from our journal.